Clinical Research Directory
Browse clinical research sites, groups, and studies.
Photodynamic Therapy for Benign Dermal Neurofibromas- Phase II
Sponsor: Donald Basel
Summary
The investigators wish to determine the time to disease progression for benign neurofibromas treated with Levulan Kerastick topical photosensitizer and red light photodynamic therapy (PDT) in patients with neurofibromatosis type 1 (NF1). The investigators also wish to measure tumor size for control and treatment tumors in order to gain insights into tumor growth rates.
Official title: Topical Photodynamic Therapy (PDT) With Levulan® Kerastick® for Benign Dermal Neurofibromas Phase II
Key Details
Gender
All
Age Range
14 Years - 30 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2016-08
Completion Date
2025-12
Last Updated
2025-05-08
Healthy Volunteers
No
Conditions
Interventions
aminolevulinic acid
Drug: Levulan Kerastick Drug: Topical placebo Device: Omnilux Revive Procedure: Photodynamic therapy Other: Tumor growth rate measurements
Locations (1)
Donald G Basel
Milwaukee, Wisconsin, United States